Sitagliptin  

CAS :486460-32-6

Sitagliptin is a new type of anti type II diabetes drug approved by FDA and the first dipeptidyl peptidase IV inhibitor drug used to treat type II diabetes. The mechanism of action of sitagliptin is different from that of previous oral hypoglycemic drugs. It can improve the pancreatic islets of diabetes patients β The ability of cells to produce Chemicalbook insulin increases insulin secretion when blood sugar rises, thus controlling the blood sugar level of diabetes patients. Clinical studies have shown that sitagliptin is an orally effective and promising drug with significant hypoglycemic effects when used alone or in combination with metformin and pioglitazone. It is safe, well tolerated, and has few adverse reactions.